Key Highlights

  • NexGel (NASDAQ:NXGL) reported third-quarter Revenue of USD 3.18 million, up 8.4% from USD 2.93 million a year earlier (calculated), while gross Margin slipped to 35.4% from 42.4%.
  • Selling, general and administrative expense rose 86.8% to USD 3.66 million, including USD 702 thousand to set up the BioNx Surgical division and USD 1.13 million of Celularity license amortization.
  • The nine-month net loss reached USD 5.57 million versus USD 1.97 million, after USD 4.58 million of Debt discount amortization and a USD 6.09 million Fair Value gain on Derivatives and warrants.
  • Unrestricted cash was only USD 278 thousand at September 30, 2026, and management reported substantial doubt about continuing as a going concern.

Biomaterials Lift Revenue but Dilute Margin

NexGel (NASDAQ:NXGL) filed its Quarterly Report on November 16, 2026 for the period ended September 30, 2026. The company manufactures electron beam cross-linked aqueous hydrogels used in wound care, diagnostics, transdermal drug delivery and cosmetics, and sells branded consumer products. Since April 2026 it also sells regenerative biomaterials for tendon repair, soft tissue reconstruction and bone regeneration after licensing and acquiring a portfolio from Celularity. Nine-month revenue rose 10.3% to USD 9.52 million, including USD 1.70 million of biomaterial sales, offset by a USD 730 thousand decline in consumer branded products. Nine-month gross margin fell to 34.6% from 42.8%, which management linked to lower-margin early biomaterial sales plus higher inventory write-offs, freight and Royalty costs.

Convertible Notes and Warrant Accounting Swing the Bottom Line

Operating loss was USD 2.54 million in the quarter against USD 0.73 million a year earlier. Net interest expense was USD 2.94 million, largely from debt discount amortization, while a USD 4.66 million fair value change in derivatives and warrants produced a quarterly net loss of USD 1.09 million, against USD 647 thousand. For nine months, those items net to a loss of USD 5.57 million. The company raised about USD 9.5 million of gross proceeds from notes in April, May and July 2026, substantially all of which funded the cash consideration for the Celularity transaction. Warrant and derivative gains are non-cash, so they do not change the underlying cash burn of USD 3.8 million used in operations over nine months.

The November 10 Recapitalization and Proposed Fountainhead Merger

On November 10, 2026 NexGel (NASDAQ:NXGL) closed note amendment and conversion agreements with holders of about USD 14.1 million of its USD 14.9 million of convertible notes, cutting the conversion price to USD 5.50 per share and the warrant exercise price to USD 13.00. The conversions depend on a proposed Merger with Fountainhead LifeSciences and affiliates, for 45% to 50% of fully diluted shares, with no definitive agreement signed. The merger is a related party matter, since Fountainhead is an affiliate of Interim Chief Executive Officer Mr. Kieser. The company also sold 281,182 shares and warrants for about USD 1.2 million. It had 536,112 shares outstanding on November 13, 2026 after a 1-for-20 reverse split, and regained Nasdaq bid price compliance on October 26, 2026.

Where Things Stand

The warrant gain is an accounting item, not cash, and the loss widened because of interest and debt discount costs. NexGel (NASDAQ:NXGL) had USD 278 thousand of unrestricted cash at September 30, 2026, and management says the merger and conversions are outside its control, so they do not remove Going Concern doubt. Revenue is growing on biomaterials, yet margins are lower and costs for the new surgical division are climbing. Next markers are a definitive Fountainhead agreement, the March 31, 2027 merger deadline in the amendments and further financing.